Xilio Therapeutics, Inc.

NASDAQ:XLO

Biotechnology

Healthcare
$7.51 +5.14%

+$0.45 today

Market cap
$53.05M
Beta
-0.09
P/E (TTM)
-48.1
EPS (TTM)
-$0.19
52W Low $6.47High $12.74

Volume 0.00M

Average 0.05M

Returns on capital

Xilio Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-99.3%

avg 34.0%

ROIC

-42.1%

avg -114.1%

ROA

-22.6%

avg -72.5%

Analysis

ROA is currently the strongest return metric at -22.6% versus its period average of -72.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Rene Russo BCPS

President, Chief Executive Officer & DirectorUSD 1.16M51——

Christopher Frankenfield

Chief Financial Officer & Chief Operating OfficerUSD 941.59K44——

Yariv Houvras

Chief Medical OfficerUSD 691.67K—105.00K1.60%

Uli Bialucha

Chief Scientific Officer————

Benjamin S. Harshbarger

Chief Legal Officer—57——

Ruth du Moulin

Senior Vice President of Medical Affairs————

Scott Coleman

Chief Development Officer————

Kevin Brennan

Senior Vice President of Finance & Accounting—56——

Nathan McBride

Chief Information Officer————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 1, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

2

$44,323.90

Sells

2

$5,696.18

Net Transaction Value

+$38,627.72

Net buying

Most Active

Shannon James Samuel

1 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Mar 26, 26

Shannon James Samuel

Direct

Buy$43.9K
Feb 13, 26

GILEAD SCIENCES, INC.

Direct

Buy$373.9
Jan 2, 26

Brennan Kevin M.

Direct

Sell$1.2K
Jan 2, 26

Frankenfield Christopher James

Direct

Sell$4.5K

Summary

Insiders reported 2 buys worth $44,323.90 and 2 sells worth $5,696.18 over the last 12 months. That adds up to net buying of $38,627.72. Shannon James Samuel was the most active insider with 1 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
-35.1% (5yr)1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Forward estimates point to Revenue at -35.1% (5yr), giving you a quick read on expected growth from here.

Competitors

Who does Xilio Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about XLO's management, answered from reported figures.

Who manages XLO?

Xilio Therapeutics, Inc. (XLO) lists 9 active executives. The top listed executive is Yariv Houvras, Chief Medical Officer.

Are XLO insiders buying or selling?

Recent insider activity shows net buying of $29.20M.